Draft synthesis: Gastrointestinal adverse events with incretin receptor agonists

§1Consultation and window

§1.1Window

Opened

24 January 2025

Closed

21 February 2025

Duration

28 days

Status

Closed — the disposition is published

Document under consultation

Synthesis: Gastrointestinal adverse events with incretin receptor agonists

Submissions received

12

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

1. Is the high certainty rating for the anchor outcome correctly drawn from the contributing evidence?
2. Is any eligible study missing from the included set, and is any included study ineligible under the registered criteria?
3. Are the limitations recorded in the abstract sufficient, and is any material limitation omitted?

§1.3How a submission is handled

• Every submission is signed. The Institute publishes no anonymous submission.
• Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
• A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
• Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
• There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

Amendments arising were applied and are recorded in the review's amendment log, each traceable to a numbered submission.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.